Country: Canada
Language: English
Source: Health Canada
EBOLA ZAÏRE VACCINE (rVSV [DELTA] G-ZEBOV-GP, LIVE)
MERCK CANADA INC
J07BX02
EBOLA VACCINES
72000000PFU
SOLUTION
EBOLA ZAÏRE VACCINE (rVSV [DELTA] G-ZEBOV-GP, LIVE) 72000000PFU
INTRAMUSCULAR
100
Schedule D
Active ingredient group (AIG) number: 0164261001; AHFS:
APPROVED
2022-11-09
_ERVEBO® (Ebola Zaire Vaccine (rVSVΔG -ZEBOV-GP, live)) _ _Page 1 of 26 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ERVEBO® Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP, live) Solution for intramuscular injection 72 million plaque forming units (pfu) per 1 mL single-dose vial of rVSVΔG-ZEBOV-GP, live Active immunizing agent Merck Canada Inc. 16750 route Transcanadienne Kirkland QC Canada H9H 4M7 www.merck.ca Date of Initial Authorization: November 9, 2022 Submission Control Number: 256568 _ERVEBO® (Ebola Zaire Vaccine (rVSVΔG -ZEBOV-GP, live)) _ _Page 2 of 26 _ RECENT MAJOR LABEL CHANGES Not applicable TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics (< 18 years of age).............................................................................. 4 1.2 Geriatrics (≥ 65 years of age) .............................................................................. 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION................................................................................. 4 4.2 Recommended Dose and Dosage Adjustment..................................................... 4 4.4 Administration................................................................................................... 4 5 OVERDOSAGE ............................................................................................................. 5 6 DOSAGE FOR Read the complete document